


FIG. 1



Part 1: Primary immunization with original strain RBD (IVX-411)
Candidate: IVX-411 (VLP with original strain RBD antigen)
Subjects: Adults (18-69 years of age); seronegative
Regimen: 2 doses on Days 0 and 28
Formulation: aqueous or formulated with oil-in-water adjuvant; 3 dose levels assessed
Part 2: Heterologous prime-boost with original strain RBD (IVX-411)
Candidate: IVX-411 (VLP with original strain RBD antigen)
Subjects: Adults (18-69 years of age); SARS-CoV-2 seropositive due to prior vaccination with approved SARS-CoV-2 vaccines
Regimen: 2 doses on Days 0 and 28
Formulation: aqueous or formulated with oil-in-water adjuvant; 3 dose levels assessed

FIG. 2



IVX-411 Phase 1/2 Trial
PHASE 1
PART1
SARS-CoV-2 Naïve Subjects
PHASE 2
PART2
Previously Vaccinated Subjects
SUPPLEMENTAL ANALYSIS
To extend evaluation of IVX-411 sera to Omicron SARS-CoV-2 variant

FIG. 3



2 DOSES
28 days apart
Placebo N=12
5, 25, or 125 µg No adjuvant N=12/grp
5, 25, or 125 µg + adjuvant N=12/grp
Dose 1
Dose 2
DAY 0
28
49
7 DAYS
Solicited AEs
49 DAYS
SAEs, AESIs, Unsolicited AEs
Immunogenicity: D0, D28 and D49
• Anti-SARS-CoV-2 Spike IgG ELISA
• SARS-CoV-2 Wild-Type, Beta, and Delta Live Virus Microneutralization
Topline Data Through D49
1 DOSE
3-6 months following completion of primary licensed vaccine regimen
Completion of primary licensed vaccine regimen
1 Dose
DAY 0
7
21
21 DAYS
SAEs, AESIs, Unsolicited AEs
Immunogenicity: D0 and D7
• Anti-SARS-CoV-2 Spike IgG ELISA
• SARS-CoV-2 Wild-Type, Beta, and Delta Live Virus Microneutralization
Topline Data Through D21

FIG. 4



PART 1
SARS-CoV-2 Naïve Subjects n=84 ADULTS (ages 18-69)
Mild
Moderate
Severe
0%
20%
40%
60%
80%
100%
Any Local AEs
5 µg
5 µg + adj
25 µg
25 µg + adj
125 µg
125 µg + adj
Placebo
Injection Site Tenderness
125 µg
125 µg + adj
Placebo
Injection Site Pain
125 µg
125 µg + adj
Placebo
Injection Site Erythema
125 µg
125 µg + adj
Placebo
Injection Site Swelling
125 µg
125 µg + adj
Placebo
PART 2
Previously Vaccinated Subjects n=84 ADULTS (ages 18-69)
Mild
Moderate
Severe
0%
20%
40%
60%
80%
100%
Any Local AEs
5 µg
5 µg + adj
25 µg
25 µg + adj
125 µg
125 µg + adj
Placebo
Injection Site Tenderness
125 µg
125 µg + adj
Placebo
Injection Site Pain
125 µg
125 µg + adj
Placebo
Injection Site Erythema
125 µg
125 µg + adj
Placebo
Injection Site Swelling
125 µg
125 µg + adj
Placebo

FIG. 5A



PART 1
SARS-CoV-2 Naïve Subjects n=84 ADULTS (ages 18-69)
Mild
Moderate
Severe
0%
20%
40%
60%
80%
100%
Any Systemic AEs
Headache
Fatigue
Myalgia
Chills
Arthralgia
Diarrhea
Fever*
5 µg
5 µg + adj
25 µg
25 µg + adj
125 µg
125 µg + adj
Placebo
PART 2
Previously Vaccinated Subjects n=84 ADULTS (ages 18-69)

FIG. 5B



Spike IgG Antibodies
Day 49 Results (BAU/mL)
No Adjuvant
+ Adjuvant
GMT (95% CI)
10000
1000
100
10
1
8
359*
15
239*
27
592*
0
361
5 µg
25 µg
125 µg
Placebo
HCS
N= 12 12 12 12 11 11 10
Fold-rise vs HCS 0.02 0.99 0.04 0.66 0.07 1.64 0.00 - -
Fold-rise vs BL 21 884 54 537 60 1466 1 - -
Seroresponse Rate 83.3 100 91.7 100 91.7 100 0 - -
Live Virus NAb to WT
Day 49 Results (IU/mL)
No Adjuvant
+ Adjuvant
GMT (95% CI)
1000
100
10
1
LLoQ
7
66*
10
94*
12
154*
6
281
5 µg
25 µg
125 µg
Placebo
HCS
N= 12 12 12 12 11 11 10
Fold-rise vs HCS 0.02 0.23 0.04 0.33 0.04 0.55 0.02 - -
Fold-rise vs BL 1.2 10.7 1.6 15.1 2.0 20.9 1.0 - -
Seroresponse Rate 0 58.3 0 75.0 16.7 58.3 0 - -

FIG. 6A



Spike IgG Antibodies
Day 0 and Day 7 Results (BAU/mL)
Day 0
Day 7
GMT (95% CI)
10000
1000
100
10
211
264
316
507
169
289
386
913
294
479
156
389
185
202
No Adj.
+ Adj.
5 µg
25 µg
125 µg
PBO
N=
Fold-rise vs BL
Seroresponse Rate
Live Virus NAb to WT
Day 0 and Day 7 Results (IU/mL)
Day 0
Day 7
GMT (95% CI)
10000
1000
100
10
99
132
105
198
99
157
177
354
157
250
74
167
99
79
LLoQ
No Adj.
+ Adj.
5 µg
25 µg
125 µg
PBO
N=
Fold-rise vs BL
Seroresponse Rate

FIG. 6B



Omicron
Day 0 and Day 49 Results
Day 0
Day 49
GMT (95% CI)
10000
1000
100
10
1
LLoQ
No Adj. 5 µg
+ Adj. 5 µg
No Adj. 25 µg
+ Adj. 25 µg
No Adj. 125 µg
+ Adj. 125 µg
PBO
N=
Fold-rise vs BL
Seroresponse Rate
Wild Type
Day 0 and Day 49 Results
Day 0
Day 49
GMT (95% CI)
LLoQ
No Adj. 5 µg
+ Adj. 5 µg
No Adj. 25 µg
+ Adj. 25 µg
No Adj. 125 µg
+ Adj. 125 µg
PBO
N=
Fold-rise vs BL
Seroresponse Rate

FIG. 7A



Omicron
Day 0, Day 7, and Day 28 Results
Day 0
Day 7
Day 28
GMT (95% CI)
1000
100
10
1
LLoQ
No Adj. 5 µg
+ Adj. 5 µg
No Adj. 25 µg
+ Adj. 25 µg
No Adj. 125 µg
+ Adj. 125 µg
PBO
N=
Fold-rise vs BL
Seroresponse Rate
Wild Type
Day 0, Day 7, and Day 28 Results
Day 0
Day 7
Day 28
GMT (95% CI)
LLoQ
No Adj. 5 µg
+ Adj. 5 µg
No Adj. 25 µg
+ Adj. 25 µg
No Adj. 125 µg
+ Adj. 125 µg
PBO
N=
Fold-rise vs BL
Seroresponse Rate

FIG. 7B